We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Masimo (MASI - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Masimo is one of 817 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. MASI is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for MASI's full-year earnings has moved 0.61% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, MASI has moved about 36.51% on a year-to-date basis. In comparison, Medical companies have returned an average of 3.76%. This shows that Masimo is outperforming its peers so far this year.
To break things down more, MASI belongs to the Medical - Instruments industry, a group that includes 92 individual companies and currently sits at #91 in the Zacks Industry Rank. This group has gained an average of 14.93% so far this year, so MASI is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to MASI as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Masimo (MASI - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Masimo is one of 817 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. MASI is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for MASI's full-year earnings has moved 0.61% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, MASI has moved about 36.51% on a year-to-date basis. In comparison, Medical companies have returned an average of 3.76%. This shows that Masimo is outperforming its peers so far this year.
To break things down more, MASI belongs to the Medical - Instruments industry, a group that includes 92 individual companies and currently sits at #91 in the Zacks Industry Rank. This group has gained an average of 14.93% so far this year, so MASI is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to MASI as it looks to continue its solid performance.